Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3160023 | 1.00 | HRH3 (0.40) | HRH3L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL21210881 | 0.98 | HRH3 (0.39) | HRH3L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL22990875 | 0.98 | HRH3 (0.39) | HRH3L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL18430268 | 0.98 | HRH3 (0.39) | HRH3L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL23032896 | 0.98 | HRH3 (0.39) | HRH3L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL22363315 | 0.98 | HRH3 (0.39) | HRH3L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL22446838 | 0.98 | HRH3 (0.39) | HRH3L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL22877461 | 0.98 | HRH3 (0.42) | HRH3L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL18387974 | 0.98 | HRH3 (0.39) | HRH3L3MBTL1MEN1KMT2ATDP1 | |
| SCHEMBL29107009 | 0.98 | HRH3 (0.39) | HRH3L3MBTL1MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340577-A1 | GCN2 INHIBITORS AND USES THEREOF | EIF2AK4, GCN1, GCGR | HRH3 2790/4885L3MBTL1 2553/4885MEN1 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.